Amryt Pharma

[Amryt Pharma]

Looking at a sales role with the company. Any feedback on the leadership or company culture would be helpful. Also how are the products performing

 

[anonymous]

Looking at a sales role with the company. Any feedback on the leadership or company culture would be helpful. Also how are the products performing

-products are old
-Leadership is stale & self absorbed (and slightly inexperienced vs industry standard)
- Exec team only seems to care about themselves. Talk a big game but all we see/feel is a bunch of hot air
- All the worthy or good people have left since the merger (field and home office)
- Compliance environment is rigid- New compliance officer assumes we are all
guilty
- pay is below industry standard

should be enough to help inform your decision. GL

 

[anonymous]

Looking at a sales role with the company. Any feedback on the leadership or company culture would be helpful. Also how are the products performing

layer on a data breech of all legacy Aegerion employees. The incompetence is ramped. The entitlement at the senior leadership level is robust. And their are just so many better companies out there that you should not have to subject yourself to this juvenile behavior.

 

[anonymous]

-products are old
-Leadership is stale & self absorbed (and slightly inexperienced vs industry standard)
- Exec team only seems to care about themselves. Talk a big game but all we see/feel is a bunch of hot air
- All the worthy or good people have left since the merger (field and home office)
- Compliance environment is rigid- New compliance officer assumes we are all
guilty
- pay is below industry standard

should be enough to help inform your decision. GL

This pretty much sums it up. Almost everyone i know is looking to get out so unless you are unemployed or looking for a depressing culture

 

[anonymous]

-products are old
-Leadership is stale & self absorbed (and slightly inexperienced vs industry standard)
- Exec team only seems to care about themselves. Talk a big game but all we see/feel is a bunch of hot air
- All the worthy or good people have left since the merger (field and home office)
- Compliance environment is rigid- New compliance officer assumes we are all
guilty
- pay is below industry standard

should be enough to help inform your decision. GL

ceo only cares about the ceo. He has zero charisma and if u hear one more time “it’s the worst disease you have never heard of” I may throw something. Work harder Joe your broken record is broken. Change the music
Everyone else acts sheepish and as if they are afraid of the ceo. Not sure why but it has become the culture

BOD is running the show. Don’t fool yourself. If you like bad music and broken records ask Amryt to dance.

 

[anonymous]

Could be interesting but they don’t have any money, do not really invest in markets and try to outsource as much as possible to distributors so that they can take the financial risk. They’re in rare disease and run it like a general pharma. Some good people like anywhere else bit get ready for instability and constant change not to mention the constant pressure as they need cash flow.

 

[anonymous]

Jury is out on Sheila. Her experience just does not seem to be aligned with this company and fear she will drive the remaining good people (which are not many) out. The string of bad decisions from the Ireland team is getting old

 

[anonymous]

Could be interesting but they don’t have any money, do not really invest in markets and try to outsource as much as possible to distributors so that they can take the financial risk. They’re in rare disease and run it like a general pharma. Some good people like anywhere else bit get ready for instability and constant change not to mention the constant pressure as they need cash flow.

Agreed, very expensive drugs with very small population base. This is expected as rare disease focus. They have no money hindering their investment. They do expect big cash flow like normal pharma bit that’s not who they are. They outsource quote a bit however ot does seem that a few distributors seem to be bailing after a while for various reasons. In summary, no investment, products are niche and almost ultra rare disease. Market is bullish on them, maybe they know something.

 

[Curious Chiasma Employee]

Seeking honest feedback about the company, culture, understanding of the rare disease markets in the US, etc. Many of us are evaluating whether to be a part of the new company after the closing but not getting much information or support from the Amryt Executive team. Guess we are looking for more than "you will a a job" from J. Wiley. Job market is very busy right now so want to make sure we/I can make as informed decisions as possible and prevent missing a good opportunity if the previous threads are accurate about the leadership of the company. Chiasma has been tough enough on us....we do not want to repeat the experience. Many thanks.

 

[anonymous]

if you are evening posting this to get feedback..trust your gut & see what is out there. This company only does things re actively and lacks vision. Sales leadership is as green as the money the execs will make on this deal and are so removed they have no idea what is going on. Godspeed

 

[anonymous]

Seeking honest feedback about the company, culture, understanding of the rare disease markets in the US, etc. Many of us are evaluating whether to be a part of the new company after the closing but not getting much information or support from the Amryt Executive team. Guess we are looking for more than "you will a a job" from J. Wiley. Job market is very busy right now so want to make sure we/I can make as informed decisions as possible and prevent missing a good opportunity if the previous threads are accurate about the leadership of the company. Chiasma has been tough enough on us....we do not want to repeat the experience. Many thanks.

 

[anonymous]

Seeking honest feedback about the company, culture, understanding of the rare disease markets in the US, etc. Many of us are evaluating whether to be a part of the new company after the closing but not getting much information or support from the Amryt Executive team. Guess we are looking for more than "you will a a job" from J. Wiley. Job market is very busy right now so want to make sure we/I can make as informed decisions as possible and prevent missing a good opportunity if the previous threads are accurate about the leadership of the company. Chiasma has been tough enough on us....we do not want to repeat the experience. Many thanks.

 

[anonymous]

Seeking honest feedback about the company, culture, understanding of the rare disease markets in the US, etc. Many of us are evaluating whether to be a part of the new company after the closing but not getting much information or support from the Amryt Executive team. Guess we are looking for more than "you will a a job" from J. Wiley. Job market is very busy right now so want to make sure we/I can make as informed decisions as possible and prevent missing a good opportunity if the previous threads are accurate about the leadership of the company. Chiasma has been tough enough on us....we do not want to repeat the experience. Many thanks.

move on, if your gut tells you something not sitting right then it isn’t for you. No harm, you choose. As for climate, new company remember they are in a very very
Limited market and getting even more so with their new drugs. Drugs are incredibly expensive and need to be taken regularly. This hinders insurance company payouts, co pays, etc. As for management well leadership is a little wanting imo but cannot speak for newer people. Biggest issue with them is small company, need lots of cashflow and run the rare disease portfolio like run of the mill pharma. Rare diseases are that, rare hence few treaters, few centers and usually patients are on all kinds of studies due to drug availability, cost, keeping doctors involved.

As other poster said, follow your gut, ask questions to the targeted physicians if you know who they are and again follow your gut.

Godspeed

 

[anonymous]

What is happening with merger? Are there rep positions available and where? Are Amryt reps training on chiasma's drug? How are your benefits? Respectfully asking. Looking for a sales position in rare disease.
Thanks!

 

[anonymous]

Legacy sales rep here --Culture has gone to the toilet. Sadly. New leadership has brought in a lot of pharma people with their own ego's and agendas. We get almost zero communication from anyone in the company and this merger will only make that that much more distant. If you hang on long enough there may be a number of sales positions open because I do not think we can, nor will the new Chiasma team, be able to tolerate this. Beware of Shiela. You have been warned. Godspeed.

 

[anonymous]

Legacy sales rep here --Culture has gone to the toilet. Sadly. New leadership has brought in a lot of pharma people with their own ego's and agendas. We get almost zero communication from anyone in the company and this merger will only make that that much more distant. If you hang on long enough there may be a number of sales positions open because I do not think we can, nor will the new Chiasma team, be able to tolerate this. Beware of Shiela. You have been warned. Godspeed.

And the new head of sales seems to fit this same mold. His track record and reputation is not good from is known. Why are these bad decisions keep happening

 

[anonymous]

Good luck, if pharma starts coming in expect them to manage rare diseases like regular pharma because that’s all they know. Who did the new head of sales replace? For such a small market with their drugs why do they need the amount of people they have? Not sure on the number but you can bet its too many. My understanding is they do not have the liquidity to continue to support any serious market development and the market itself does not lend to it either.

to be continued, as far as reputations go tis best to get your own opinion.
Best of luck to all, meanwhile I’ll go update my resume!!!!

 

[anonymous]

Good luck, if pharma starts coming in expect them to manage rare diseases like regular pharma because that’s all they know. Who did the new head of sales replace? For such a small market with their drugs why do they need the amount of people they have? Not sure on the number but you can bet its too many. My understanding is they do not have the liquidity to continue to support any serious market development and the market itself does not lend to it either.

to be continued, as far as reputations go tis best to get your own opinion.
Best of luck to all, meanwhile I’ll go update my resume!!!!

Brian L was in charge of commercial but that suddenly seemed to change without notice when Shiela arrived. She has her own plan apparently & feel like we find out every day about someone new who has been hired in a leadership role. If liquidity is a challenge then what are they hiring so many top heavy roles ? Because historically they have been very very cheap

 

[anonymous]

Sadly, and what feels to have happened quite quickly we have become a 'pharma' company and the rare disease vibe and focus has been pushed aside. SF was the first domino in all of this and we can never look back now. Everything just feels so unemotional and procedural. Guess that is why we have memories to hold on to. Just does not feel right anymore

 

[anonymous]

Sadly, and what feels to have happened quite quickly we have become a 'pharma' company and the rare disease vibe and focus has been pushed aside. SF was the first domino in all of this and we can never look back now. Everything just feels so unemotional and procedural. Guess that is why we have memories to hold on to. Just does not feel right anymore

SF and BG are trying to take a primary care sales force approach. Do these idiots really think that every physician in the community has a patient? I can’t wait to leave this place.